Alkermes plc. (ALKS) stock
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30208% above fair value
$46.85+1.40 (+3.08%)
Close on Nov 18, 2026Market cap $7.86BP/E 123.3Yield –
Alkermes gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Alkermes's gross profit for the twelve months ending Jun 30, 2026 was $1.41B, up 10.0% year over year. For fiscal 2025 it was $1.28B, down 2.5% from the year before. Over ten years it grew 10.1% a year on average. The highest annual figure on record is $1.41B in fiscal 2023.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.28B | -2.5% |
| FY2024 | Dec 31, 2024 | $1.31B | -7.0% |
| FY2023 | Dec 31, 2023 | $1.41B | +57.8% |
| FY2022 | Dec 31, 2022 | $893.73M | -8.5% |
| FY2021 | Dec 31, 2021 | $976.43M | +13.5% |
| FY2020 | Dec 31, 2020 | $860.44M | -13.1% |
| FY2019 | Dec 31, 2019 | $990.56M | +7.9% |
| FY2018 | Dec 31, 2018 | $917.85M | +22.6% |
| FY2017 | Dec 31, 2017 | $748.63M | +22.0% |
| FY2016 | Dec 31, 2016 | $613.57M | +25.4% |
| FY2015 | Dec 31, 2015 | $489.35M | +20.8% |
| FY2013 | Mar 31, 2013 | $405.08M | +54.4% |
| FY2012 | Mar 31, 2012 | $262.40M | +95.2% |
| FY2011 | Mar 31, 2011 | $134.46M | +4.4% |
| FY2010 | Mar 31, 2010 | $128.84M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $397.90M | +16.6% |
| Q1 FY2026 | Mar 31, 2026 | $331.33M | +28.8% |
| Q4 FY2025 | Dec 31, 2025 | $338.34M | -8.0% |
| Q3 FY2025 | Sep 30, 2025 | $342.59M | +8.7% |
| Q2 FY2025 | Jun 30, 2025 | $341.20M | +1.0% |
| Q1 FY2025 | Mar 31, 2025 | $257.31M | -11.8% |
| Q4 FY2024 | Dec 31, 2024 | $367.87M | +19.7% |
| Q3 FY2024 | Sep 30, 2024 | $315.04M | -1.4% |
| Q2 FY2024 | Jun 30, 2024 | $337.66M | -39.1% |
| Q1 FY2024 | Mar 31, 2024 | $291.73M | +27.2% |
| Q4 FY2023 | Dec 31, 2023 | $307.35M | +22.6% |
| Q3 FY2023 | Sep 30, 2023 | $319.44M | +58.3% |
| Q2 FY2023 | Jun 30, 2023 | $554.15M | +154.4% |
| Q1 FY2023 | Mar 31, 2023 | $229.43M | +2.7% |
| Q4 FY2022 | Dec 31, 2022 | $250.75M | -7.4% |
| Q3 FY2022 | Sep 30, 2022 | $201.73M | -17.5% |
| Q2 FY2022 | Jun 30, 2022 | $217.86M | -13.1% |
| Q1 FY2022 | Mar 31, 2022 | $223.39M | +6.2% |
| Q4 FY2021 | Dec 31, 2021 | $270.85M | +14.2% |
| Q3 FY2021 | Sep 30, 2021 | $244.58M | +10.2% |
| Q2 FY2021 | Jun 30, 2021 | $250.59M | +23.8% |
| Q1 FY2021 | Mar 31, 2021 | $210.41M | +5.7% |
| Q4 FY2020 | Dec 31, 2020 | $237.07M | -35.3% |
| Q3 FY2020 | Sep 30, 2020 | $221.88M | +4.2% |
| Q2 FY2020 | Jun 30, 2020 | $202.48M | -13.3% |
| Q1 FY2020 | Mar 31, 2020 | $199.01M | +12.0% |
| Q4 FY2019 | Dec 31, 2019 | $366.25M | +37.4% |
| Q3 FY2019 | Sep 30, 2019 | $212.92M | +1.7% |
| Q2 FY2019 | Jun 30, 2019 | $233.65M | -10.6% |
| Q1 FY2019 | Mar 31, 2019 | $177.74M | -1.6% |
| Q4 FY2018 | Dec 31, 2018 | $266.65M | +12.6% |
| Q3 FY2018 | Sep 30, 2018 | $209.31M | +15.4% |
| Q2 FY2018 | Jun 30, 2018 | $261.23M | +45.9% |
| Q1 FY2018 | Mar 31, 2018 | $180.67M | +19.4% |
| Q4 FY2017 | Dec 31, 2017 | $236.86M | +32.7% |
| Q3 FY2017 | Sep 30, 2017 | $181.33M | +25.2% |
| Q2 FY2017 | Jun 30, 2017 | $179.07M | – |
| Q1 FY2017 | Mar 31, 2017 | $151.37M | – |
| Q4 FY2016 | Dec 31, 2016 | $178.56M | – |
| Q3 FY2016 | Sep 30, 2016 | $144.79M | – |
See a number that looks wrong?